Synergy of Guideline-Directed Medical Therapies in Heart Failure to Optimize Patient Outcomes - a podcast by ReachMD

CME credits: 0.50

Valid until: 15-12-2022

Claim your CME credit at https://reachmd.com/programs/cme/synergy-of-guideline-directed-medical-therapies-in-heart-failure-to-optimize-patient-outcomes/13115/

Renin-angiotensin-aldosterone system inhibition (RAASi) is the foundation of guideline-directed medical therapy (GDMT) for heart failure patients. However, due to practice gaps, a significant proportion of the population requiring its use do not experience the benefits of RAASi therapy, which is especially true for patients with comorbid conditions. Hyperkalemia is a common adverse effect of RAASi therapy that needs to be anticipated and mediated so that the optimal dosing of necessary medications can occur. Maximizing GDMT in the face of hyperkalemia remains a key clinical challenge that, if not handled properly, can result in increased morbidity and mortality.

In this activity, Drs. Javed Butler, Mikhail Kosiborod, and Matthew Weir review a patient case and discuss different treatment approaches to optimize GDMT while managing hyperkalemia. Tune in to make sure you’re doing all you can to improve outcomes for your patients with heart failure and comorbid conditions.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD